Navigation Links
VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
Date:11/26/2007

Xyfid in the first half of 2008. In addition, VioQuest and the U.S. Army are planning to submit a New Drug Application (NDA) to the U. S. Food and Drug Administration (FDA) in 2008 for Lenocta for the treatment of leishmaniasis.

Further information about VioQuest can be found at http://www.vioquestpharm.com.

This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These forward-looking statements concern the timing, progress and results of the clinical development, regulatory processes, and potential clinical trial initiations of Lenocta. These statements are often, but not always, made through the use of words or phrases such as anticipates, expects, plans, believes, intends, and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. These statements are subject to various risks and uncertainties and include the possibility that the results of clinical trials will not support VioQuest's claims, the possibility that VioQuest's development efforts relating to its product candidates, including Lenocta(TM), will not be successful, the inability to obtain regulatory approval of VioQuest's product candidates, VioQuest's reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2006. VioQuest assumes no obligation
'/>"/>

SOURCE VioQuest Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 24, 2015 Hi-Tech Pharmaceuticals refutes the ... the product of reliable scientific principles and methods ... for allegations of adulteration. The FDA is resting ... premise, or misguided hope, that Methylphenylethylamine is not ... contradicted by multiple other studies and cannot be ...
(Date:4/24/2015)... April 24, 2015  Blueprint Medicines today announced ... and potent inhibitor of fibroblast growth factor receptor ... of hepatocellular carcinoma (HCC) that are dependent on ... induced complete tumor regression in a subset of ... at the highest dose levels. These data will ...
(Date:4/23/2015)... - Health Canada is working with the Canadian manufacturers ... information regarding the risk of serious cardiovascular side effects ... used at high doses (at or above 2400 mg/day). ... Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) ... inflammation. The majority of ibuprofen products in ...
Breaking Medicine Technology:Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 3Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 4Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 5Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 6Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 2Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 3Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 4
(Date:4/25/2015)... The impact of the Trivedi Master ... of the public and is likely to cause further, ... and June. From March 21st to March 31st, ... "Special Prayers." More than 600 people participated in the ... and have reported intense experiences that they attest have ...
(Date:4/25/2015)... April 25, 2015 The URO CENTER of ... has been chosen by the New York Academy of Medicine ... medicine in the field of Urology. , Dr. Ferdinand Valentine, ... speciality, Genito-Urinary diseases. He was a man of rare ... of urology. Not only did he devote his life ...
(Date:4/24/2015)... 2015 Bird B Gone, the leader in ... offers a complete line of bird control solutions to address ... New Flu Strains Threaten Pacific, Central and Mississippi Farms , ... , a number of highly pathogenic avian flus in the ... often spread when wild birds enter poultry farms. The USDA ...
(Date:4/24/2015)... Ryadon is a leading manufacturer of custom ... services to complement any custom hardware requirements you may ... be offered on all heavy duty drawer slides ( ... discount - Order 20+: Receive 20% discount , Industries ... Furniture ,Drawer Slides, Inc. ...
(Date:4/24/2015)... 2015 The 1975 have had ... across the globe to theaters, festivals and TV performances. Now ... partnered with their label, Dirty Hit Records, to provide clean ... the newly launched Cadence & Cause website, this ... on vinyl and a signed photo card. Entries from ...
Breaking Medicine News(10 mins):Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 2Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 4Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3Health News:Internationally Recognized British Indie Rock Outfit The 1975 Partner with Cadence & Cause to Provide Clean Drinking Water to Those in Need 2
... 28 Nutrition 21, Inc.,(Nasdaq: NXXI ), ... consumers manage blood sugar levels, improve cardiovascular health,enhance ... two new,additions to its Iceland Health(R) brand portfolio: ... Plus SLEEP Support.,Formulated with omega-3 fish oil and ...
... Noor came to,the attention of the Battalion Commander of ... Brigade Combat Team through an,unfortunate shooting incident from a ... little girl,s uncle. The initial diagnosis made by Lt.,Col. ... blind,due to a birth defect that resulted in poorly ...
... 28 OrbusNeich today announced that it,has received approval ... R stent in Taiwan., The Genous stent is ... cells (EPCs) circulating in the bloodstream. When,attracted to the ... shown to,quickly form a healthy layer of endothelium that ...
... 28 Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ... New Drug Application (NDA) for oxybutynin,chloride topical gel ... U.S. Food,and Drug Administration (FDA). Watson is seeking ... hydrochloride for the treatment of,overactive bladder (OAB)., ...
... account for nearly all of the increase in U.S. singleton ... national birth data. , Between 1996 and 2004 there ... 92 percent of those infants were delivered by a cesarean ... of Dimes and the U.S. Centers for Disease Control and ...
... 27 It is estimated that there were ... Did you know that,African-American women have a 50 ... A new campaign, One4One, is empowering women to,help ... increase cervical,cancer education programs for women in multicultural ...
Cached Medicine News:Health News:Nutrition 21 Launches Iceland Health(R) Cholesterol Health and Iceland Health(R) Joint Relief Plus SLEEP Support 2Health News:Nutrition 21 Launches Iceland Health(R) Cholesterol Health and Iceland Health(R) Joint Relief Plus SLEEP Support 3Health News:Nutrition 21 Launches Iceland Health(R) Cholesterol Health and Iceland Health(R) Joint Relief Plus SLEEP Support 4Health News:Photos: Los Angeles Non Profit Teams With US Troops Stationed in Baghdad and Buaytha in Bringing a 5-Year-Old Blind Iraqi Girl, Whose Father Stands Beside US Combat Team Against Al Qaeda, to the US for a Groundbreaking Artificial Corneal Transplant Surger 2Health News:OrbusNeich Receives Approval to Market Genous(TM) Bio-engineered R stent(TM) in Taiwan 2Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 2Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 3Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 4Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 5Health News:C-sections a critical factor in preterm birth increase 2
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
... SDX is one of the ... Implantable with a 7 F ... diameter is designed to lower ... and allow introduction in smaller, ...
... The Vitatron Crystalline Active fixation ... with a new extendable retractable helix ... performance of the pacemaker system, reducing ... and myopotentials. The Crystalline Active fixation ...
Medicine Products: